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ABSTRACT
Introduction: Technical and logical breakthroughs have provided new opportunities in medicine to use 
knowledge bases and large-scale clinical data (real-world) at point-of-care as part of a learning health-
care system to diminish the knowledge-practice gap.
Areas covered: The article is based on presentations, discussions and recommendations from an interna-
tional scientific workshop. Value, research needs and funding avenues of knowledge bases and access to 
real-world data as well as transparency and incorporation of patient perspectives are discussed.
Expert opinion: Evidence-based, publicly funded, well-structured and curated knowledge bases are of 
global importance. They ought to be considered as a public responsibility requiring transparency and 
handling of conflicts of interest. Information has to be made accessible for clinical decision support 
systems (CDSS) for healthcare staff and patients. Access to rich and real-world data is essential for 
a learning health care ecosystem and can be augmented by data on patient-reported outcomes and 
preferences. This field can progress by the establishment of an international policy group for develop-
ing a best practice guideline on the development, maintenance, governance, evaluation principles and 
financing of open-source knowledge bases and handling of real-world data.
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1. Introduction: the evolving role of information 
communication technology in healthcare
Information communication technology (ICT) is transforming 
medical practice, including the relationships between patients 
and healthcare personnel [1,2]. It is essential for clinicians and 
researchers to identify and communicate important avenues for 
the development of the infrastructure needed for clinical deci-
sion support systems. This narrative review from an international 
workshop held in 2019 at Karolinska Institute, Stockholm (see 
Section 1.6 Methods), aims to support such a dialogue with 
decision-makers in healthcare and relevant authorities.
The focus of the workshop was to present, discuss and advise 
on how to progress in particular the appropriate use of knowl-
edge bases in clinical practice as well as the useful compilation of 
real-world data to evaluate the rational use of medicines in daily 
work and promote scientific studies. The access to well- 
structured knowledge bases on drug therapy and the availability 
of software to extract real-world data on prescribing practices 
have progressed this area markedly in the recent decade. The 
expert meeting focused on the pharmacotherapeutic area. Still, 
the covered subjects on ensuring the use of unbiased and scien-
tific sound information are valid in all other areas where knowl-
edge bases are integrated into CDSS.
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Real-world data (RWD, see Appendix 1), defined as data 
relating to patient health status or the delivery of health care, 
are routinely collected from a variety of sources, most impor-
tantly from electronic health records (EHRs). New types of 
data, such as patient-reported outcome measures (PROMs) 
are collected in healthcare or through health apps and perso-
nal devices [3]. PROMs provide insights on the impact disease 
and treatment has on patients’ lives [4].
Electronic health records have been widely adopted across 
primary and secondary care in most high-income countries 
and are increasingly linked to tools for diagnosis, treatment, 
patient monitoring and telemedicine. Developing countries 
without developed or wide-spread IT-infrastructure might 
benefit quickly from new open standards and terminology 
and free access to curated knowledge databases. The use of 
mobile devices and web resources with application program-
ming interfaces (APIs) may support healthcare in developing 
countries at a low cost.
Analysis of RWD can generate evidence, real-world evi-
dence (RWE), for instance, about the usage and potential 
benefits or risks of medicines and medical products. RWE can 
thus support both regulatory and clinical decisions [5]. The use 
of large datasets generated in healthcare to support decision 
making is a rapidly developing field [6,7].
A health record can be structured, presented and visualized 
in many ways, for instance, by using a time-, source-, protocol-, 
or problem-oriented paradigm [8]. Different modes of presen-
tation may depend on different goals of the user, whether 
they, for instance, refer to a new patient, a re-reading of 
a known patient, searching for facts or focusing on problem- 
solving. Flexible integrated visualization of clinical datasets is 
a crucial concept that might support collaboration and shared 
decision making with the patient [9,10].
Semantic interoperability between CDSS and EHRs can be 
achieved through EHRs being organized in a problem-oriented 
manner guided by SOAP-principles (Subjective, Objective, 
Assessment, Plan) [11], the standards for health record content 
and structure (OpenEHR, ISO-13606), as well as for health 
information exchange (HL7 CDA, IHE, FHIR) and agreed ter-
minologies applied (e.g., ATC, ICPC, ICD and SNOMED-CT).
1.1. Real-world data
Electronic health records offer a rich source of RWD. Data 
mining of EHRs can, for instance, identify signals of possible 
adverse drug events that can enrich individual case safety 
reports [12,13]. EHRs are valuable sources often used in obser-
vational studies and enables combining healthcare data with 
either patient data extracted from clinical or quality registries, 
using static features or more complex temporal abstractions 
[14]. In this way, observational studies may provide new 
insights and generate broader sets of evidence compared to 
randomized controlled trials (RCTs) [15,16].
Pragmatic RCTs combine inclusion/exclusion/randomiza-
tion with follow-up and monitoring through EHRs and clinical 
registries. The concept makes it possible to study clinically 
relevant questions (with limitations such as not being blinded 
in the healthcare) that otherwise would be unresolved due to 
lack of resources/time, financial constraints or due to strict 
inclusion criteria in RCTs [17–19].
Patient reported outcome measures, especially those rele-
vant for the quality of life, are helpful for shared decision 
making within routine care. The use of PROMs in clinical 
decision-making can significantly improve outcomes for 
patients, in some cases, even overall survival when compared 
to usual care [20]. The development and use of PROMs in 
clinical care require attention to ensure that data collection 
is made easy for patients and that such data are integrated 
within the EHR and made available as part of the clinical 
workflow to influence the care given. PROMs are also essential 
components to consider in the development of future knowl-
edge bases, informing more data-driven CDSS.
International differences in data protection laws and ethical 
policies have to be considered to enable the use of patient 
data at the individual level for both clinical practice and 
research. While specific health claims analyses with record 
linkage between hospital and ambulatory care can be con-
ducted, for instance, in the USA, they are still a challenge in 
Germany [21]. Reasons for the disparity between countries are 
among others differences in implementation of EHRs between 
countries and in (health) data protection laws [22]. For the 
European Union (EU), a special regulation from 2016, specifies 
requirements for the analysis of personal data and free move-
ment of such data [23]. Other laws consider the electronic 
exchange of health data between member states [24,25].
1.2. Knowledge bases
Decisions in medical practice require both extensive informa-
tion about the patients and their medical history and easy 
access to evidence in systematic reviews and guidelines based 
on RCTs. Knowledge bases are deployed to feed decision rules 
in CDSS.
The content of knowledge bases can be translated into 
clinical decision rules, applied in CDSS. These systems may 
consist of simple tasks, such as alerts, reminders, critique or 
Article highlights
● Evidence-based knowledge bases are essential sources for clinical 
decision support systems (CDSS). Real-world data (RWD) from elec-
tronic health records and patient-reported outcomes can if curated 
provide broader sets of evidence compared to randomized controlled 
trials. Analysis of RWD can diminish the evidence-practice gap in 
medicine.
● CDSS need to incorporate complex situations and offer weighed 
results instead of being single factor-based decision aids. Available 
guidelines considering context, content, system and implementation 
can ensure CDSS fit workflow and avoid alert fatigue among users.
● Open science approaches improve visibility and citation of research, 
increases collaboration, reduces collective cost and increase the 
quality of data. Barriers to sharing data can be reduced through 
legislation such as the new Finnish legislation on secondary use of 
health data that facilitates big data analysis and is possible by new 
methods to analyze encrypted data.
● Critical strategies for the future include: a/ public funding of open 
knowledge bases; b/ an international collaboration of guideline for 
best practices and ethics on developing and managing knowledge 
bases and handling conflict of interests; c/ establishing a digital 
resource archive of tools and resources; and d/ communicating 
research and development priorities.
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more complex tasks, including interpreting data, supporting 
diagnosis, predicting an outcome, assisting orders/prescrip-
tions and presenting suggestions for improvement [9,26]. 
The demands on CDSS have evolved to include support for 
complex decisions, e.g. in patients with multimorbidity and 
polypharmacy.
Knowledge bases represent the cornerstones of CDSS in 
healthcare. How these databases are compiled and curated 
and then distributed and implemented in CDSS is critical. 
Knowledge bases with open access such as several curated 
by the National Library of Medicine in the USA have shown the 
impact of using open interfaces or APIs and open data in 
standard formats [27].
The task of gathering, assimilating, digesting, and synthe-
sizing evidence from RCTs is daunting. Especially for the use in 
daily care, several suites of point-of-care evidence summaries 
have been developed [28]. The MAGIC project is a nonprofit 
initiative that maintains open-source tools for multi-layer 
designed guideline development adapted for multi-channel 
digital use [29]. The aim is to support the development of 
guidelines based on well-defined clinical questions at PICO- 
level (Patient/Intervention/Comparator/Outcome).
Knowledge bases with reviewed evidence from RCTs sup-
port decisions regarding the efficacy of pharmacological pre-
vention and treatment. However, the nature, transparency, 
and rigor of evidence in support of the safety of medicines 
(adverse effects, drug-drug interactions and dosage strategies) 
are often unclear. Hence, transparency is needed regarding 
methods for data collection, development of evidence and 
translation of information into clinical guidelines and treat-
ment recommendations.
1.3. Clinical decision support systems
It is assumed that medication-related decision support can 
deliver significant value by improving safety and efficiency. 
However, this assertion is not supported by the results of 
systematic reviews [30–32]. CDSSs over time have shown 
effects on practitioner performance for more straightforward 
tasks, such as drug dosing and preventive care decisions but 
not convincingly presented value in diagnostic support. The 
impacts of CDSSs on patient outcomes have been insuffi-
ciently studied [30–32]. Alert fatigue is common when using 
CDSSs today. A few studies of the effects of CDSS on specific 
patient-reported outcomes have shown marginal positive 
effects on specific patient-reported outcomes [33]. Providing 
CDSS also to patients slightly increased adherence [34]. 
Reviews of factors impeding or facilitating implementations 
of CDSS in healthcare have highlighted the complexity of this 
task [34,35].
A few vendors have driven the development and imple-
mentation of CDSS in the USA [36]. The situation in Europe is 
different [37]. Developing and distributing quality-assured 
knowledge bases and guidelines based on algorithms are in 
Europe mostly viewed as national projects funded either pub-
licly or in partnership with private developers [37].
It is a significant task to develop CDSS that help clinicians 
improve practice [38]. Hence, the CDSS need to incorporate 
complex situations, and offer weighed results instead of being 
single-factor based decision aids. Practical obstacles for this 
include poor functional integration with commercially avail-
able EHRs [39,40]. Additionally, the lack of integration with 
work processes and deficiencies in the human-computer inter-
face (Graphical User Interface, GUI) limit the usefulness of the 
tools and information. There are GUI guidelines for medica-
tion-related CDSS [39,40], but the CDSS is just one part of how 
healthcare personnel interact with the EHR [41].
An essential approach to avoid alert fatigue and improve 
the usability of CDSS is to follow evidence-based approaches 
to user interface design and human-computer interaction in 
the development of CDSS. A recent study on visual design 
factors affecting emergency physicians in clinical decision- 
making scenarios showed that greater complexity in visual 
design was dissatisfying for many physicians. In contrast, time-
lines and highlighting can offer effective and efficient inter-
faces when, for instance, reviewing medication histories [42].
The Guideline Implementation with Decision Support 
(GUIDES) checklist summarizes best practices for successful 
implementation and governance of CDSS [43]. It consists of 
four CDSS domains (context, content, system, implementation), 
with four factors in each domain. The checklist is the result of an 
international collaboration headed by the Norwegian Institute 
of Public Health. Another approach is summarized as the ten 
commandments for effective CDSS by Bates et al. [44–46] cover-
ing a range of parameters such as speed, the importance of the 
CDSS to match clinical work processes, continuous feedback and 
the need for evaluations [44,45].
Information communication technology has provided clin-
icians and researchers opportunities to compare treatment 
practices and outcomes using RWD from EHR or regional/ 
national health and quality registers [47–49]. During the past 
two decades, intervention studies have shown that feeding 
patient-level outcome data back to practicing physicians and 
researchers are effective ways to improve care when com-
bined with educational improvement interventions [48,50–52].
These two approaches – knowledge base information 
accessed through a CDSS and querying patient-level outcome 
data through web-based interfaces – have been introduced 
across a range of health care systems. However, their demon-
strated impact on the quality of care has varied considerably.
Different reasons have contributed to this variation, for 
example, uneven quality of data and lack of agreements on 
principles to indicate fair and unbiased evaluation of data 
[1,18,53], and the challenges of performing high-quality 
assessments within complex interconnected socio-technical 
systems, interlinked organizational issues, and increasing 
legal regulations [54].
1.4. Knowledge databases – evidence from multiple 
sources
The term semantic web introduced by the World Wide Web 
Consortium (W3C) [55] refers to the internet with an abun-
dance of linked data. Several factual knowledge bases have 
been made available online, offering computerized reasoning 
on different data sets [56]. These databases can potentially 
provide input to CDSSs that uses artificial intelligence to gen-
erate new knowledge. Today these systems are often 
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nontransparent for the users, and their validity for use in 
healthcare has to be demonstrated.
Access to diverse data from multiple sources with variable 
levels of specificity and validity call for new methods for data 
mining. One such approach is a multimodal analysis that fuses 
heterogeneous data sets (for example text, audio, video and 
sensor data) to derive more accurate information than what is 
possible by considering each data source separately [57]. 
Multimodal analysis can be combined with semantic analysis 
by applying a combination of neural networks, semantic par-
sing, and knowledge graphs, to analyze text-rich knowledge 
bases and information gathered from EHRs [57].
1.5. Supporting shared decision-making
Decision aids for patients, including pamphlets, videos or web- 
based tools, can improve patients’ knowledge of available 
options and better inform them about matters of personal 
importance. There is some evidence that these aids will help 
patients to gain more accurate expectations of benefits and 
harms of competing treatment options, and to participate in 
a higher degree in making the decisions [58]. However, there 
is a lack of evidence on whether interventions to increase the 
use of shared decision making by healthcare professionals are 
effective [59,60].
There are two significant challenges in creating tools to 
support shared decision-making in chronic conditions – how 
to support decision-making both initially and repeatedly; and 
how to support decision-making for patients with chronic 
conditions. Even tasks perceived as ‘simple’, such as support-
ing decisions about polypharmacy, are hampered by clinical 
guidelines that rarely account for multimorbidity, lack 
a patient-centered approach, do not consider patient prefer-
ences and are poorly integrated with over-arching care plan-
ning processes [61,62].
1.6. Methods
In response to these opportunities and challenges, an interna-
tional expert workshop was organized at Karolinska Institutet 
in Stockholm and by the independent foundation Swedish 
Institute for Drug Informatics (SIDI) in January 2019. The pur-
pose was to define guiding principles for the development 
and application of knowledge bases (Definition 2 Appendix) in 
Computerized Decision Support System (CDSS, Definition 3 
Appendix) and the use of RWD to improve quality of 
pharmacotherapy.
This Expert review summarizes the key findings from the 
workshop. It is not a formal systematic review as the main 
emphasis was to capture the views of a wide range of senior 
researchers and policy personnel in this field to provide future 
direction. The basis for part 1 (Introduction including 
Methods) and 2 (Main conclusions) are the manuscripts for 
the presentations during the workshop. Part 3 (Expert opinion) 
is a consensus document agreed upon by all participants at 
the end of the workshop.
Presentations and workshop sessions are openly available 
online as videocasts and as pdf-presentations at the website of 
Karolinska Institutet https://ki.se/en/labmed/public-videocast- 
of-ki-international-workshop-in-stockholm-january-2019.
2. Conclusions from the workshop
2.1. Success factors for the implementation of CDSSs
Tools for successful implementation and governance of 
a CDSS, such as GUIDES, are helpful but pragmatic. They 
should specify the importance of factors that are feasible to 
measure while placing less emphasis on the goals of the CDSS 
and the origin and quality of the underlying data. Such guides 
would gain trust by emphasizing professional values like will-
ingness to learn, to collaborate with colleagues, and to form 
and maintain a learning environment. There are only a few 
good prospective studies on the perceived value and effects 
on patient outcomes of developing and implementing CDSS 
in out- and inpatient care [37].
Resources must be allocated to support the implementa-
tion of a CDSS until it is established as an evaluated routine in 
clinical care. The specific needs of different stakeholders have 
to be considered, e.g. patients and their healthcare profes-
sionals, EHR vendors and Standard Developing Organizations 
(SDOs), as well as healthcare policymakers [63].
2.2. New approaches in building a CDSS
Today CDSSs are largely rule-based systems, but new 
approaches including data mining, artificial intelligence, 
machine learning and deep learning have the potential to 
supplement traditional algorithm-based approaches [56,64]. 
A deep-learning approach could support clinical decisions in 
several ways, including by direct suggestions of alternative 
diagnostic and treatment choices. Transparency is, however, 
limited with machine learning techniques, and unintentional 
biases can be introduced [65,66].
To be accepted for clinical use, specific criteria must be 
met, and any suggested systems require scientific evaluation. 
Examples of criteria are fairness (using training data and mod-
els free of bias), robustness (not vulnerable to tampering or 
compromising the data they are trained on), explainability 
(explaining for the user how decisions or suggestions have 
been made) and life-cycle auditing of the system [65].
Transparency regarding the primary data and assumptions 
leading to the recommendations are essential for building 
trust. Openly available rules applied to present and interpret 
scientific information are necessary for transparency but 
would have significant commercial implications, e.g. as appar-
ent in the USA today [36].
2.3. Coordinated efforts are needed
The Finnish Medical Society Duodecim has for three decades 
been the key actor in developing not only evidence-based 
treatment guidelines but also national knowledge bases and 
CDSS in Finland [67]. The approach demonstrates the impor-
tance of a long-term vision and plan for development, imple-
mentation and evaluation on a national scale.
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The guidelines are available as a platform-independent 
commercial service integrated with all EHRs in Finland. 
A generic decision support client is provided, capable of inter-
acting with various EHR systems, allowing editing and docu-
menting of decision rules, and potentially interfacing with 
external knowledge bases. A primary goal of the system is 
not only to address the needs of healthcare practitioners but 
also those of the patients. The system allows combined ana-
lyses of individual patients and population data to determine 
care gaps and to measure clinical quality based on patient- 
level data [68,69]. This infrastructure demonstrates how sys-
tems can be used both in clinical practice and on different 
population levels to understand gaps in care and evaluate the 
outcome of quality interventions for improvement of care [67].
Even good-quality datasets with excellent metadata require 
that third parties thoroughly analyze the data to understand 
how to use the data set appropriately. The advantages of open 
science are that it improves visibility and citation of research, 
increases collaboration, reduces collective cost, and improves 
the quality of data.
Barriers to sharing patient-level data can be reduced through 
legislation such as the new Finnish legislation on secondary use 
of health data that facilitates big data analysis [70], by policies 
and incentives supporting better data citation and collaboration. 
Sharing sensitive data can be facilitated by new methods to 
analyze encrypted data. Generation of synthetic data sets may 
preserve the main characteristics of interest to the study as well 
as prevent re-identification of a patient [71].
Standards and common representations ought to make an 
understanding of shared datasets easier [72]. Data fragmentation 
and lack of data interoperability still constitute a considerable 
barrier to accessing and using data. To accelerate the use of 
datasets research on new ways to pursue cost-effectiveness 
studies using encrypted techniques ought to be stimulated.
Knowledge bases, on the other hand, represents 
a compilation of structured knowledge. They don’t contain sen-
sitive patient-level data and can thus be shared widely if issues of 
copyright and responsibility for the process are solved. 
A significant development is the strive for more open knowledge 
bases based on the FAIR guiding principles for scientific data 
management and stewardship (Findable, Accessible, 
Interoperable, Reusable) [73]. FAIR differs from earlier domain- 
focused initiatives in that it describes concise, domain- 
independent, high-level principles that can be applied to 
a wide range of scholarly outputs and handles both data and 
metadata. The FAIR principles are supported by, among others, 
NLM and the NIH in the USA [74]. The strategic plan for the NLM 
for 2017–2027 envisions NLM as a platform for biomedical dis-
covery and data-powered health, integrating streams of complex 
and interconnected research outputs that can be readily trans-
lated into scientific insights, clinical care, public health practices 
and personal wellbeing [75].
3. Expert opinion
The participating experts agreed on the need for action within 
four different strategic areas:
● Public funding of open knowledge bases.
● An international collaboration of guideline for best prac-
tices and ethics on developing and managing knowl-
edge bases.
● Establishing a digital resource archive of tools and 
resources.
● Communicating research and development priorities for 
the future.
Goals for the future include to:
● develop and communicate a vision on how knowledge 
bases could be of value outside the country/region pro-
viding a business case for public and charity-based non-
commercial funding of knowledge bases in medicine,
● summarize success stories on the value of knowledge 
bases in different settings,
● emphasize the need for knowledge bases to support 
CDSS addressing complex treatment situations (such as 
multimorbidity and polypharmacy) and patient prefer-
ences in difficult treatment situations,
● partner with medical associations and other professional 
organizations to form a small task force and take the first 
step in ensuring public awareness of the possibilities 
with public-funded knowledge bases in a global perspec-
tive based on the strategic importance of development 
aid supporting the Universal Health Coverage (UHC) 
principles [76], and
● develop international guidance on procedures and prac-
tices of developing, managing and evaluating values of 
knowledge bases.
3.1. Public funding of open knowledge bases
There is a need to define and provide access to essential drug 
information for optimal care in resource-strained countries 
[77,78]. With relatively limited funding, many sources of infor-
mation developed across the globe could become available in 
resource-strained countries by joint initiatives from learned 
societies, public funders and private-public partnerships and 
using already existing available technology platforms. Well- 
structured evidence-based knowledge bases using interna-
tional nomenclatures and standards support the pursuit of 
excellence and efficiency in healthcare. Providing governance 
following agreed principles such as FAIR is essential for accep-
tance and use in healthcare organizations and other countries.
Public funding of trustworthy databases (such as the ‘Guide to 
pharmacology, immunopharmacology and drugs for malaria’ [79]) 
may provide high value to healthcare systems in other countries – 
regardless of the level of economic development and IT- 
maturity. Resource-strained countries might be able to leapfrog 
by getting access to such information. The development, finan-
cing and stewardship of such knowledge bases constitute a cost- 
effective approach for supporting healthcare systems in these 
countries. It was agreed that participants of this workshop could 
lobby for such funding together with research groups and inter-
national expert organizations, for instance, International Union of 
Basic and Clinical Pharmacology (IUPHAR) or the Council for 
International Organizations of Medical Sciences (CIOMS).
EXPERT REVIEW OF CLINICAL PHARMACOLOGY 929
Some of the information sources currently available are 
commercial products and as such, not freely available for 
everyone. The authors strongly argue for openness and trans-
parency whenever possible. Every purchaser of commercial 
knowledge bases and CDSS should demand that the algo-
rithms and knowledge bases deployed are suitably documen-
ted and approved by an independent group of experts.
3.2. International collaboration of guideline for best 
practices and ethics on developing and managing 
knowledge bases
There is a need to compile an inventory of existing guidelines 
regarding best practices for development and use of knowledge 
bases in clinical medicine and education based on the FAIR [73] 
and GUIDES [43] principles. The development of a guideline 
should focus on expanding Domain 2.1 on evidence-based infor-
mation in the GUIDES checklist for computerized decision sup-
port [43]. Such a detailed and international multi-partner 
developed, trusted and used guideline for best practices and 
ethics on developing and managing knowledge bases on the 
rational use of medicines is presently lacking. It should:
● Be developed by an international and independent 
multi-stakeholder expert working group recruited across 
countries, stakeholders and disciplines and hosted by 
a trusted international body or a group of bodies (such 
as CIOMS, IUPHAR or the GUIDES-consortium).
● Be governed by the principles of open science and state 
that publicly funded knowledge bases require open access 
to data for everyone in order to be useful and trusted in 
clinical practice. It should also contain explanations of 
computational approaches and policies for handling biases.
● State on what premises commercial partners can inte-
grate information and design tools so that trust and 
transparency are maintained in support of evidence- 
based principles.
● Agree on a Standard Operating Procedure (SOP) about 
principles for identifying needs of information, collection, 
evaluation, presentation and structuring of data with 
requirements for procedures for implementation, gov-
ernance, user feedback and evaluation of perceived 
value in clinical practice and educational settings.
● Outline governing principles that ensure long-term 
multi-professional competence and appropriate roles 
for healthcare professions, scientists, technical staff and 
between the management and the board.
● Suggest the principles for a structure of a knowledge 
base and guidance on important collaborating partners, 
including maintaining open access for repositories.
● Explore options for sustainable funding.
3.3. Establishing a digital resource archive of tools and 
resources
The creation of a digital resource archive for tools and resources – 
a repository for decision support – ought to be prioritized. The 
archive should be a curated set of open-source analysis tools, 
knowledge bases, and data sets made freely available for 
research. This would allow researchers to leverage previous 
efforts and compare their work to the state of the art. Such 
proposed repositories ought to follow the FAIR-principles [73] 
and use a certification such as CoreTrustSeal [80]. For the sake of 
quality and reproducibility, all resources need to be versioned, 
and previous versions kept. Both knowledge bases and data sets 
can be multimodal, combining text, x-rays, speech transcriptions 
and population statistics. In Europe, efforts are ongoing to con-
nect different research data repositories within the European 
Open Science Cloud project [81]. Standards for documentation 
and handling of data are developed within the Data 
Documentation Initiative (DDI) [82] and the Research Data 
Alliance (RDA) [83]. Another open-source effort is the initiative 
Open-CDS that aim to develop open-source, standards-based 
tools and resources for CDSS [84] and an emerging interoper-
ability standard for sharing research evidence within Health Level 
Seven International (HL7) initiative [85].
The digital resource archive should ideally have a dedicated 
organization and secured long-term funding, to ensure that all 
published resources are of sufficient quality and that the 
infrastructure is maintained. An example of a broad research 
data repository is the Swedish National Data Service (SND) [86] 
that runs a distributed system in collaboration with all major 
Swedish universities. This archive could collaborate with the 
Swedish healthcare regions as well as with private caregivers 
who are willing to share their assets. This could stimulate 
research and innovation in their respective area.
We encourage the managers of digital archives to establish 
close links to national research councils. If developed into 
a pan-European initiative, EU-funding is feasible due to its 
public goods nature. The participating experts agreed to strive 
for this to happen and, when possible, to start sharing their 
information sources.
3.4. Research and development priorities for the future
Methodology for the creation of decision rules
● Design knowledge bases that are based on technology- 
agnostic, detailed clinical models and can serve as input 
to and output of clinical decision rules.
● Design and development of tools for editing decision 
rules from structured information in knowledge bases.
● Design CDSS systems that can incorporate decision rules 
from several independent knowledge bases offering trans-
parency into the recommendation-deduction process.
● Design CDSS systems that can interact with various EHRs 
in primary care and Electronic Patient Dossier systems in 
hospitals.
● Development of methods for the clinical validation of 
CDSS systems based on artificial intelligence, AI.
Enriching real-world data for use in CDSS
● Test the feasibility of using multisource RWD, for inform-
ing population-level decisions in healthcare and for sup-
porting education.
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● Design CDSS systems that can combine clinical data from 
medical records with the patient-generated outcome 
and preference data.
● Increase the knowledge among health care professionals 
regarding CDSS, medical informatics and possibilities of 
using RWD during basic education or to provide learning 
opportunities for professionals later in their career.
Ensuring the inclusion of the patient perspective
● Design, development and test of CDSS tools addressing 
complex healthcare situations (multimorbidity and poly-
pharmacy) incorporating patient preferences for care 
and therapy.
● Development of applications allowing stream-lined 
multi-site development and governance of knowledge 
bases, including twinned systems for patient and health-
care staff needs.
Strengthening the evidence base on the effectiveness of CDSS 
systems
● Engage in comparative studies of acceptability and effi-
cacy of CDSS-systems on patient outcome parameters.
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Appendix Some key definitions
1: Real-world data (RWD)
Information on health care and health that is derived from multiple 
sources outside typical clinical research settings including EHR, claims and 
billing data, product, quality and disease registries, socioeconomic 
information and data gathered through personal devices and applications. 
We have to separate information reported and validated as compared to 
data gathered from social media, which commonly express perceptions.
Real-world data is rich in information but commonly lack quality. Well- 
structured and adequately collected patient-reported outcome measures 
(PROMs) can be of high quality and relevant for the specific disease. It can 
be of high relevance for estimating the effectiveness of the treatment 
among real and more heterogeneous patients (as opposed to efficacy in 
clinical trials) by following relevant effects when estimating the efficiency 
of an intervention [49,87].
A central issue is trustworthiness, especially when it is supposed to be 
used for formal decision-making as in regulatory science. This is a crucial 
dimension in validating decision support systems based on artificial intel-
ligence. Transparency in how the data-collection process was carried out 
has to be guaranteed and the results tested under strict conditions, 
preferably in randomized control trials. New methods for simplifying 
accuracy and security are needed to be developed.
2: Knowledgebase
A knowledgebase is an abstract collection of facts, organized to sup-
port logical inference and induction. A knowledge-based system can meet 
demands that a traditional database cannot handle. In knowledgebases, 
data is commonly structured, defined and linked to each other by various 
ontologies [88].
3: Clinical decision support system (CDSS)
Clinical decision support (CDS) provides clinicians, staff, patients or 
other individuals with knowledge and person-specific information, intelli-
gently filtered or presented at appropriate times, to enhance health and 
health care. CDS encompasses a variety of tools to enhance decision- 
making in the clinical workflow. A clinical decision support system 
(CDSS) can be defined as the use of the computer to bring knowledge 
of relevance in health care and for the wellbeing to a specific patient 
adopted to her characteristics [89].
4: Learning health care system (two definitions)
A system in which science, culture, incentives and informatics are 
aligned for continuous improvement and innovation. Best practices are 
seamlessly embedded in the care process with patients and their families 
as active participants and new knowledge captured as an integral by- 
product of the care [90].
A learning health system is designed to generate and apply the best 
evidence for the collaborative healthcare choices of each patient and 
provider, to drive the process of discovery as a natural outgrowth of 
patient care and to ensure innovation, quality, safety, and value in health 
care [91].
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